The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020
Open accessPublished version of a preprint
Abstract
Two new SARS-CoV-2 lineages with the N501Y mutation in the receptor-binding domain of the spike protein spread rapidly in the United Kingdom. We estimated that the earlier 501Y lineage without amino acid deletion Δ69/Δ70, circulating mainly between early September and mid-November, was 10% (6–13%) more transmissible than the 501N lineage, and the 501Y lineage with amino acid deletion Δ69/Δ70, circulating since late September, was 75% (70–80%) more transmissible than the 501N lineage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A B.1.1.7 isolate had signature changes in the spike gene14 including the 69–70 and 144–145 deletions, and N501Y, A570D, D614G, and P681H substitutions.”
From Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies (2021) · cites this paper as [14]
In the citing paper
“Epidemiological studies suggest that it was approximately 50% more transmissible than previously circulating UK variants 191,197,198 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [197]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments
Price, M. N., Dehal, P. S., & Arkin, A. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009490 · Cited by 14,894
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535
Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956
SARS-CoV-2 evolution during treatment of chronic infection
Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature · doi:10.1038/s41586-021-03291-y · Cited by 1,097
Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity
Volz, E., Hill, V., McCrone, J. T., Price, A., Jorgensen, D., O’Toole, Á., Southgate, J., Johnson, R., Jackson, B., Nascimento, F. F., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.020 · Cited by 1,006
Leung, K. S. M., Wu, J. T. K., Liu, D., & Leung, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30746-7 · Cited by 840
Self-citationNeutralising antibodies in Spike mediated SARS-CoV-2 adaptationPreprint
Kemp, S. A., Collier, D. A., Datir, R. P., et al. (2020) · medRxiv · doi:10.1101/2020.12.05.20241927 · Cited by 180
Nasal ACE2 Levels and COVID-19 in Children
Patel, A. B., & Verma, A. (2020) · JAMA · doi:10.1001/jama.2020.8946 · Cited by 143
Research works printed but not linked: 1
- Kemp, 2020, Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion ΔH69/ΔV70, bioRxiv
Cited by
Sorted by citations
Mechanisms of SARS-CoV-2 entry into cells
Jackson, C. B., Farzan, M., Chen, B., & Choe, H. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00418-x · Cited by 3,022
Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England
The COVID-19 Genomics UK (COG-UK) consortium, Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., et al. (2021) · Nature · doi:10.1038/s41586-021-03470-x · Cited by 1,611
Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881
The biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
Hoffmann, M., Arora, P., Groß, R., Seidel, A., Hörnich, B. F., Hahn, A. S., Krüger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.036 · Cited by 897
“V1, emerged in the United Kingdom and was associated with a surge of COVID-19 cases (Kidd et al., 2021; Leung et al., 2021).”
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
Turner, J. S., O’Halloran, J. A., Kalaidina, E., Kim, W., Schmitz, A. J., Zhou, J. Q., Lei, T., Thapa, M., Chen, R. E., Case, J. B., et al. (2021) · Nature · doi:10.1038/s41586-021-03738-2 · Cited by 831
Estimating infectiousness throughout SARS-CoV-2 infection course
Jones, T. C., Biele, G., Mühlemann, B., Veith, T., Schneider, J. A., Beheim-Schwarzbach, J., Bleicker, T., Tesch, J., Schmidt, M. L., Sander, L. E., et al. (2021) · Science · doi:10.1126/science.abi5273 · Cited by 752
“8 increase in transmission (54), and an estimate of a 43% to 90%higher reproductive number (55).”
BackgroundCherian, S., Potdar, V. A., Jadhav, S., Yadav, P. D., Gupta, N., Das, M., Rakshit, P., Singh, S. K., Abraham, P., Panda, S., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9071542 · Cited by 726
Emary, K. R. W., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00628-0 · Cited by 603
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
Jones, B. E., Brown‐Augsburger, P., Corbett, K. S., Westendorf, K., Davies, J., Cujec, T. P., Wiethoff, C. M., Blackbourne, J. L., Heinz, B. A., Foster, D., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf1906 · Cited by 546
The N501Y spike substitution enhances SARS-CoV-2 infection and transmission
Liu, Y., Liu, J., Plante, K. S., Plante, J. A., Xie, X., Zhang, X., Ku, Z., An, Z., Scharton, D., Schindewolf, C., et al. (2021) · Nature · doi:10.1038/s41586-021-04245-0 · Cited by 575
Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
Deng, X., Garcia-Knight, M. A., Khalid, M. M., Servellita, V., Wang, C., Morris, M. K., Sotomayor-González, A., Glasner, D. R., Reyes, K. R., Gliwa, A. S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.025 · Cited by 651
“accumulated 17 lineage-defining mutations, including the spike protein N501Y mutation that confers increased transmissibility over other circulating viruses (Leung et al., 2021; Rambaut et al., 2020b; Volz et al., 2020).”
BackgroundSARS‐CoV‐2 Omicron variant: Characteristics and prevention
He, X., Hong, W., Pan, X., Lu, G., & Wei, X. (2021) · MedComm · doi:10.1002/mco2.110 · Cited by 513
The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant
Tian, D., Sun, Y., Xu, H., & Ye, Q. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27643 · Cited by 474
“Compared with the early original strains, many clinical studies have suggested that Alpha, Beta, and Delta variants increase the risk of hospitalization, ICU admission, and death.(8,9,11,12) Previously reported cases from South Africa(46) and 43 cases of Omicron in the United States(53,54) found that the symptoms of c…”
BackgroundEffect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity
Gobeil, S., Janowska, K., McDowell, S., Mansouri, K., Parks, R., Stalls, V., Kopp, M., Manne, K., Li, D., Wiehe, K. J., et al. (2021) · Science · doi:10.1126/science.abi6226 · Cited by 385
N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2
Tian, F., Tong, B., Sun, L., Shi, S., Zheng, B., Wang, Z., Dong, X., & Zheng, P. (2021) · eLife · doi:10.7554/elife.69091 · Cited by 394
Covid‐19 vaccines and variants of concern: A review
Hassine, I. H. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2313 · Cited by 418
COVID-19 and Cardiovascular Disease
Chung, M. K., Zidar, D. A., Bristow, M. R., Cameron, S. J., Chan, T. A.-T., Harding, C. V., Kwon, D. H., Singh, T. K., Tilton, J. C., Tsai, E. J., et al. (2021) · Circulation Research · doi:10.1161/circresaha.121.317997 · Cited by 377
Khan, A., Zia, T., Suleman, M., Khan, T., Ali, S. S., Abbasi, A. A., Mohammad, A., & Wei, D. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30367 · Cited by 341
“…the SARS‐CoV‐2 RBD domain can serve as an important target for designing the anti‐COVID‐19 therapeutic strategies (Lan et al., 2020) Recent reports from England regarding the origin of novel contagious strain (B.1.1.7) of SARS‐CoV‐2 have further exacerbated the situation (Leung et al., 2021).”
BackgroundInfluentialBroad and potent activity against SARS-like viruses by an engineered human monoclonal antibody
Rappazzo, C. G., Tse, L. V., Kaku, C. I., Wrapp, D., Sakharkar, M., Huang, D., Deveau, L. M., Yockachonis, T. J., Herbert, A. S., Battles, M. B., et al. (2021) · Science · doi:10.1126/science.abf4830 · Cited by 307
Chatterjee, S., Bhattacharya, M., Nag, S., Dhama, K., & Chakraborty, C. (2023) · Viruses · doi:10.3390/v15010167 · Cited by 325
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
Dong, J., Zost, S. J., Greaney, A. J., Starr, T. N., Dingens, A. S., Chen, E. C., Chen, R. E., Case, J. B., Sutton, R. E., Gilchuk, P., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00972-2 · Cited by 285
Cherian, S., Potdar, V., Jadhav, S., Yadav, P., Gupta, N., Das, M., Rakshit, P., Singh, S., Abraham, P., Panda, S., et al. (2021) · doi:10.1101/2021.04.22.440932 · Cited by 730
Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
Saunders, K. O., Lee, E., Parks, R., Martinez, D. R., Li, D., Chen, H., Edwards, R. J., Gobeil, S., Barr, M., Mansouri, K., et al. (2021) · Nature · doi:10.1038/s41586-021-03594-0 · Cited by 253
Deng, X., Garcia-Knight, M. A., Khalid, M. M., Servellita, V., Wang, C., Morris, M. K., Sotomayor-González, A., Glasner, D. R., Reyes, K. R., Gliwa, A. S., et al. (2021) · doi:10.1101/2021.03.07.21252647 · Cited by 651
COVID-19 and metabolic disease: mechanisms and clinical management
Steenblock, C., Schwarz, P. E. H., Ludwig, B., Linkermann, A., Zimmet, P., Kulebyakin, K. Y., Va, T., Markov, A. G., Lehnert, H., de Angelis, M. H., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00244-8 · Cited by 256
Hoffmann, M., Hofmann-Winkler, H., Krüger, N., Kempf, A., Nehlmeier, I., Graichen, L., Arora, P., Sidarovich, A., Moldenhauer, A.-S., Winkler, M. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109415 · Cited by 258
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Hwang, Y., Lu, R., Su, S.-C., Chiang, P.-Y., Ko, S.-H., Ke, F.-Y., Liang, K.-H., Hsieh, T.-Y., & Wu, H. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-021-00784-w · Cited by 247
Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2
Baggen, J., Persoons, L., Vanstreels, E., Jansen, S., Looveren, D. V., Boeckx, B., Geudens, V., Man, J. D., Jochmans, D., Wauters, J., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00805-2 · Cited by 215
Sallam, M., Dababseh, D., Eid, H., Hasan, H., Taim, D., Al-Mahzoum, K., Al-Haidar, A., Yaseen, A. I. B., Ababneh, N. A., Assaf, A. M., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18052407 · Cited by 202
The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape
Tian, D., Sun, Y., Zhou, J., & Ye, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.751778 · Cited by 201
Proteolytic activation of SARS‐CoV‐2 spike protein
Takeda, M. (2021) · Microbiology and Immunology · doi:10.1111/1348-0421.12945 · Cited by 194
COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies
Raman, R., Patel, K. J., & Ranjan, K. (2021) · Biomolecules · doi:10.3390/biom11070993 · Cited by 194
SARS‐CoV‐2 Alpha, Beta, and Delta variants display enhanced Spike‐mediated syncytia formation
Rajah, M. M., Hubert, M., Bishop, E., Saunders, N., Robinot, R., Grzelak, L., Planas, D., Dufloo, J., Gellenoncourt, S., Bongers, A., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108944 · Cited by 192
“Some studies proposed that the N501Y mutation may provide a replication advantage, whereas others suggested that N501Y is deleterious (Hou et al , 2020; Frampton et al , 2021; Leung et al , 2021; preprint: Liu et al , 2021a).”
Emerging SARS-CoV-2 variants expand species tropism to murines
Shuai, H., Chan, J. F., Yuen, T. T., Yoon, C., Hu, J., Wen, L., Hu, B., Yang, D., Wang, Y., Hou, Y., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103643 · Cited by 166
Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants
Han, P., Su, C., Zhang, Y., Bai, C., Zheng, A., Qiao, C., Wang, Q., Niu, S., Chen, Q., Zhang, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26401-w · Cited by 166
The N501Y spike substitution enhances SARS-CoV-2 transmission
Liu, Y., Liu, J., Plante, K. S., Plante, J. A., Xie, X., Zhang, X., Ku, Z., An, Z., Scharton, D., Schindewolf, C., et al. (2021) · doi:10.1101/2021.03.08.434499 · Cited by 574
Giacomo, S. D., Mercatelli, D., Rakhimov, A. N., & Giorgi, F. M. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27062 · Cited by 159
The outbreak of SARS‐CoV‐2 Omicron lineages, immune escape, and vaccine effectivity
Zhou, Y., Zhi, H., & Teng, Y. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28138 · Cited by 155
Focosi, D., & Maggi, F. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2231 · Cited by 150
The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK
Hill, V., du Plessis, L., Peacock, T. P., Aggarwal, D., Colquhoun, R., Carabelli, A. M., Ellaby, N. A. F., Gallagher, E., Groves, N., Jackson, B., et al. (2022) · Virus Evolution · doi:10.1093/ve/veac080 · Cited by 145
“It is now clear that Alpha was associated with a higher transmission rate than the background D614G lineages that dominated in the UK at the time (Davies, Abbott, et al. 2021; Leung et al. 2021; Volz et al. 2021) as well as a higher case fatality rate (Davies, Jarvis, et al. 2021).”
BackgroundFrom delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants
PAPANIKOLAOU, V. S., Chrysovergis, A., Ragos, V., Tsiambas, E., Katsinis, S., Manoli, A., Papouliakos, S. M., Roukas, D., Mastronikolis, S. N., Peschos, D., et al. (2022) · Gene · doi:10.1016/j.gene.2021.146134 · Cited by 149
“…human transmissibility/infectivity, disease phenotype severity and partially limited efficacy (immune escape) to vaccine and antibody therapeutic strategies due to low immune response rates (Gobeil et al., 2021; Daniloski et al., 2021; Luan et al., 2021; Nelson et al., 2021; Hoffmann et al., 2021).”
Lustig, Y., Zuckerman, N. S., Nemet, I., Atari, N., Kliker, L., Regev‐Yochay, G., Sapir, E., Mor, O., Alroy‐Preis, S., Mendelson, E., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.26.2100557 · Cited by 143
Characterization of the Second Wave of COVID-19 in India
Ranjan, R., Sharma, A., & Verma, M. K. (2021) · Current Science · doi:10.18520/cs/v121/i1/85-93 · Cited by 139
Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines
Zhou, W., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00644-x · Cited by 134
“These preliminary pieces of evidence indicate that the N501Y mutation may increase transmissibility.(8,22) Besides, Kristian Andersen identified another notable feature of SARS-CoV-2 that the spike protein has a functional polybasic (Furin) cleavage site.”
BackgroundHow to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19
Accorsi, E. K., Qiu, X., Rumpler, É., Kennedy‐Shaffer, L., Kahn, R. J., Joshi, K., Goldstein, E., Stensrud, M. J., Niehus, R., Çevik, M., et al. (2021) · European Journal of Epidemiology · doi:10.1007/s10654-021-00727-7 · Cited by 128
The emerging SARS-CoV-2 variants of concern
Sanyaolu, A. O., Okorie, C., Marinkovic, A., Haider, N., Abbasi, A. F., Jaferi, U., Prakash, S., & Balendra, V. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361211024372 · Cited by 122
Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis
Thye, A. Y.-K., Law, J. W., Pusparajah, P., Letchumanan, V., Chan, K., & Lee, L. (2021) · Biomedicines · doi:10.3390/biomedicines9101303 · Cited by 121
Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
Zhou, Y., Xie, Y., Tang, L., Pu, D., Zhu, Y., Liu, J., & Ma, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00733-x · Cited by 116
The Spike of Concern—The Novel Variants of SARS-CoV-2
Winger, A., & Caspari, T. (2021) · Viruses · doi:10.3390/v13061002 · Cited by 122
Chen, X., Chen, Z., Azman, A. S., Sun, R., Lu, W., Zheng, N., Zhou, J., Wu, Q., Deng, X., Zhao, Z., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab646 · Cited by 113
Grabowski, F., Preibisch, G., Giziński, S., Kochańczyk, M., & Lipniacki, T. (2021) · Viruses · doi:10.3390/v13030392 · Cited by 112
Ferasin, L., Fritz, M., Ferasin, H., Becquart, P., Corbet, S., Gouilh, M. A., Legros, V., & Leroy, E. M. (2021) · Veterinary Record · doi:10.1002/vetr.944 · Cited by 113
Gushchin, V. А., Dolzhikova, I. V., Shchetinin, A. M., Odintsova, A. S., Siniavin, A. E., Nikiforova, M. A., Pochtovyi, A. A., Shidlovskaya, E. V., Kuznetsova, N. A., Burgasova, O., et al. (2021) · Vaccines · doi:10.3390/vaccines9070779 · Cited by 110
Montero, C. G., Fraile‐Μartinez, O., Bravo, C., Torres‐Carranza, D., Sánchez‐Trujillo, L., Gomez-Lahoz, A. M., Guijarro, L. G., García‐Honduvilla, N., Asúnsolo, Á., Buján, J., et al. (2021) · Vaccines · doi:10.3390/vaccines9050433 · Cited by 112
Rosa, G. L., Mancini, P., Ferraro, G. B., Veneri, C., Iaconelli, M., Lucentini, L., Bonadonna, L., Brusaferro, S., Brandtner, D., Fasanella, A., et al. (2021) · Water Research · doi:10.1016/j.watres.2021.117104 · Cited by 109
Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways
Iwata‐Yoshikawa, N., Kakizaki, M., Shiwa-Sudo, N., Okura, T., Tahara, M., Fukushi, S., Maeda, K., Kawase, M., Asanuma, H., Tomita, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33911-8 · Cited by 109
HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens
Fischer, W., Giorgi, E. E., Chakraborty, S., Nguyen, K., Tanmoy Bhattacharya, A., Theiler, J. P., Goloboff, P. A., Yoon, H., Abfalterer, W., Foley, B. T., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.05.012 · Cited by 109
“N501Y enhances infectivity with a modest impact on neutralization (Leung et al., 2021; Rathnasinghe et al., 2021).”
Evaluation and Comparison of Serological Methods for COVID-19 Diagnosis
Gong, F., Wei, H.-X., Li, Q., Liu, L., & Li, B. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.682405 · Cited by 109
Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals
Meekins, D. A., Gaudreault, N. N., & Richt, J. A. (2021) · Viruses · doi:10.3390/v13101993 · Cited by 105
The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape
Tian, D., Sun, Y., Zhou, J., & Ye, Q. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27376 · Cited by 106
“7 was first detected in New York in November 2020.(22) B.”
BackgroundSpherical Neutralizing Aptamer Inhibits SARS-CoV-2 Infection and Suppresses Mutational Escape
Sun, M., Liu, S., Song, T., Chen, F., Zhang, J., Huang, J.-A., Wan, S., Lu, Y. W. W., Chen, H., Tan, W., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c08226 · Cited by 98
Increased transmissibility of SARS-CoV-2 lineage B.1.1.7 by age and viral load
Lyngse, F. P., Mølbak, K., Skov, R. L., Christiansen, L. E., Mortensen, L. H., Albertsen, M., Møller, C. H., Krause, T. G., Rasmussen, M., Michaelsen, T. Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27202-x · Cited by 88
Dhakal, S., Ruiz-Bedoya, C. A., Zhou, R., Creisher, P. S., Villano, J., Littlefield, K. E., Castillo, J. R., Marinho, P. M., Jedlicka, A., Ordoñez, A. A., et al. (2021) · mBio · doi:10.1128/mbio.00974-21 · Cited by 96
Schubert, M., Bertoglio, F., Steinke, S., Heine, P. A., Ynga-Durand, M. A., Maaß, H., Sammartino, J. C., Cassaniti, I., Zuo, F., Du, L., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02312-5 · Cited by 92
Viral Vectors for COVID-19 Vaccine Development
Lundstrom, K. H. (2021) · Viruses · doi:10.3390/v13020317 · Cited by 94
The origins of COVID‐19 pandemic: A brief overview
Hao, Y., Wang, Y., Wang, M.-Y., Zhou, L., Shi, J., Cao, J., & Wang, D. (2022) · Transboundary and Emerging Diseases · doi:10.1111/tbed.14732 · Cited by 139
Ramírez, S., Fernandez-Antunez, C., Galli, A., Underwood, A. P., Pham, L. V., Ryberg, L. A., Feng, S., Pedersen, M. S., Mikkelsen, L. S., Belouzard, S., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00097-21 · Cited by 89
Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity
Gong, S. Y., Chatterjee, D., Richard, J., Prévost, J., Tauzin, A., Gasser, R., Bo, Y., Vézina, D., Goyette, G., Gendron‐Lepage, G., et al. (2021) · Virology · doi:10.1016/j.virol.2021.09.001 · Cited by 81
Salleh, M. Z., Derrick, J. P., & Deris, Z. Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147425 · Cited by 82
Model-driven mitigation measures for reopening schools during the COVID-19 pandemic
McGee, R. S., Homburger, J. R., Williams, H., Bergstrom, C. T., & Zhou, A. Y. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2108909118 · Cited by 80
Zhao, S., Lou, J., Cao, L., Zheng, H., Chong, K. C., Chen, Z., Chan, R. W. Y., Zee, B. C.-Y., Chan, P. K. S., & Wang, M. H. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab011 · Cited by 77
Ma, H., Zeng, W., Meng, X., Huang, X., Yang, Y., Zhao, D., Zhou, P., Wang, X., Zhao, C., Sun, Y. C., et al. (2021) · Journal of Virology · doi:10.1128/jvi.02438-20 · Cited by 75
Advances in the design and development of SARS-CoV-2 vaccines
Peng, X., Cheng, J., Gong, H., Yuan, M.-D., Zhao, X., Li, Z., & Wei, D. (2021) · Military Medical Research · doi:10.1186/s40779-021-00360-1 · Cited by 84
Case, J. B., Chen, R. E., Cao, L., Ying, B., Winkler, E. S., Johnson, M., Goreshnik, I., Pham, M. N., Shrihari, S., Kafai, N. M., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.008 · Cited by 73
Leung, K. S. M., Wu, J. T. K., & Leung, G. M. (2021) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00167-5 · Cited by 79
Self-citationThe global transmission of new coronavirus variants
Zhao, Y., Huang, J., Zhang, L., Chen, S., Gao, J., & Jiao, H. (2021) · Environmental Research · doi:10.1016/j.envres.2021.112240 · Cited by 73
Antiviral Activities of Algal-Based Sulfated Polysaccharides
Panggabean, J. A., Adiguna, S. P., Rahmawati, S. I., Ahmadi, P., Zainuddin, E. N., Bayu, A., & Putra, M. Y. (2022) · Molecules · doi:10.3390/molecules27041178 · Cited by 76
“The emergence of a few new variants—including the Alpha variant in the United Kingdom (B.1.1.7), the Beta variant (B.1.351) in South Africa [4], the Gamma variant in Japan and Brazil (B.1.1.28.1), and the Delta variant (B.1.617.2) in India [5], as well as the newly discovered Omicron variant in South Africa (B.1.1.529…”
BackgroundInfluentialMolecular diagnostic assays for COVID-19: an overview
Habibzadeh, P., Mofatteh, M., Silawi, M., Ghavami, S., & Faghihi, M. A. (2021) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2021.1884640 · Cited by 77
“75% more transmissible than previous variants [15].”
Effectiveness of Natural Antioxidants against SARS-CoV-2? Insights from the In-Silico World
Rehman, M. F. U., Akhter, S., Batool, A. I., Selamoğlu, Z., Sevindik, М., Eman, R., Mustaqeem, M., Akram, M. S., Kanwal, F., Lu, C., et al. (2021) · Antibiotics · doi:10.3390/antibiotics10081011 · Cited by 77
SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines
Khan, A., Khan, T., Ali, S., Aftab, S., Wang, Y., Wang, Q., Khan, M., Suleman, M., Ali, S., Heng, W., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112176 · Cited by 75
Nanotechnology‐Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID‐19 Vaccines
Rinoldi, C., Zargarian, S. S., Nakielski, P., Li, X., Liguori, A., Petronella, F., Presutti, D., Wang, Q., Costantini, M., Sio, L. D., et al. (2021) · Small Methods · doi:10.1002/smtd.202100402 · Cited by 78
Schepens, B., van Schie, L., Nerinckx, W., Roose, K., Breedam, W. V., Fijałkowska, D., Devos, S., Weyts, W., Cae, S. D., Vanmarcke, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abi7826 · Cited by 66
Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?
Hamady, A., Lee, J., & Loboda, Z. (2021) · Infection · doi:10.1007/s15010-021-01664-z · Cited by 66
Vitamin D and COVID-19: An Overview of Recent Evidence
Ghelani, D. P., Alesi, S., & Mousa, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910559 · Cited by 71
Vega‐Magaña, N., Sánchez-Sánchez, R., Hernández‐Bello, J., Venancio-Landeros, A. A., Rodríguez, M. P., Vega-Zepeda, R. A., Galindo-Ornelas, B., Díaz-Sánchez, M., García‐Chagollán, M., Ojeda, G. M., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.672562 · Cited by 67
“Mutation N501Y has been found on the receptor-binding domain (RBD) and has been associated with an increase of binding affinity to the ACE2 receptor (Starr et al., 2020; Leung et al., 2021).”
BackgroundAn ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants
Tanaka, S., Nelson, G., Olson, C. A., Buzko, O. V., Higashide, W., Shin, A., Gonzalez, M. R., Taft, J. D., Patel, R. S., Buta, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91809-9 · Cited by 65
Lane, C. R., Sherry, N. L., Porter, A. F., Duchêne, S., Horan, K., Andersson, P., Wilmot, M., Turner, A., Dougall, S., Johnson, S. A. S., et al. (2021) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00133-x · Cited by 68
Coronavirus Infection and Cholesterol Metabolism
Dai, J., Wang, H., Liao, Y., Tan, L., Sun, Y., Song, C., Liu, W., Qiu, X., & Ding, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.791267 · Cited by 68
Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail
Dong, J., Zost, S. J., Greaney, A. J., Starr, T. N., Dingens, A. S., Chen, E. C., Chen, R. E., Case, J. B., Sutton, R. E., Gilchuk, P., et al. (2021) · doi:10.1101/2021.01.27.428529 · Cited by 55
Extracellular vesicles mediate antibody-resistant transmission of SARS-CoV-2
Xia, B., Pan, X., Luo, R., Shen, X., Li, S., Wang, Y., Zuo, X., Wu, Y. L., Guo, Y., Xiao, G., et al. (2023) · Cell Discovery · doi:10.1038/s41421-022-00510-2 · Cited by 67
One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages
Gónzález‐Candelas, F., Shaw, M., Phan, T. G., Kulkarni‐Kale, U., Paraskevis, D. N., Luciani, F., Kimura, H., & Sironi, M. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104869 · Cited by 65
Hetemäki, I., Kääriäinen, S., Alho, P., Mikkola, J., Savolainen‐Kopra, C., Ikonen, N., Nohynek, H., & Lyytikäinen, O. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.30.2100636 · Cited by 65
B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies
Zhan, Y., Yin, H. Y., & Yin, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.66881 · Cited by 68
“7 has attracted attention [4, 5], because there is no previous evidence that variation will increase the adaptability of SARS-CoV-2 genome.”
BackgroundJhun, H., Park, H., Hisham, Y., Song, C., & Kim, S. (2021) · Immune Network · doi:10.4110/in.2021.21.e32 · Cited by 65
“2) variant was first detected in India in October 2020 (48-50) and has become the most prevalence variant in the European countries in the middle of April 2021 according to European Centre for Disease Prevention and Control.”
BackgroundChung, H., Jian, M., Chang, C.-K., Lin, J., Yeh, K., Chen, C., Hsieh, S., Hung, K., Tang, S. W., Perng, C., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02513-21 · Cited by 84
Souza, P. F. N., Mesquita, F. P., Amaral, J. L., Landim, P. G. C., Lima, K. R. P., Costa, M. B., Farias, I. R., Belém, M. O., Pinto, Y. O., Moreira, H. H. T., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.03.058 · Cited by 67
Banada, P. P., Green, R., Banik, S., Chopoorian, A., Streck, D. L., Jones, R., Chakravorty, S., & Alland, D. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00845-21 · Cited by 61
“The N501Y (A23063T) mutation has been identified as an important contributor to the worrisome phenotype (2, 4, 10, 11).”
BackgroundHirotsu, Y., & Omata, M. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.03.013 · Cited by 64
Structural genetics of circulating variants affecting the SARS-CoV-2 spike/human ACE2 complex
Ortuso, F., Mercatelli, D., Guzzi, P. H., & Giorgi, F. M. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1886175 · Cited by 61
Metadata
- Authors
- Leung, K., Shum, M. H., Leung, G. M., Lam, T. T., & Wu, J. T.
- Affiliations
- Laboratory of Data Discovery for Health (HK)
- Joint Institute of Virology (Shantou University and The University of Hong Kong), Guangdong-Hongkong Joint Laboratory of Emerging Infectious Diseases, Shantou University, Shantou, China
- Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, New Territories, Hong Kong SAR, China
- Corresponding author
- Wu, Joseph T
- Venue
- Eurosurveillance
- Published
- 2021-01-07
- Volume
- 26
- Issue
- 1
- ISSN
- 1025-496X (ISSN-L)
- 1560-7917
- PMC
- PMC7791602
- OpenAlex
- W3120079728
- Cited by
- 694
- References
- 12
- Citations by year
- 2026: 3 · 2025: 14 · 2024: 24 · 2023: 90 · 2022: 176 · 2021: 385
- FWCI
- 53.29
- Type
- journal article
- Language
- en
- Update notices
- addendum (2021-01-21)
- Open access
- diamond
- doi.org
- Locations
- Eurosurveillance (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (31922087)
- Hong Kong Government
- Health and Medical Research Fund
- Young Scientists Fund
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, N501Y mutation, spike protein receptor-binding domain, viral transmissibility, United Kingdom, COVID-19 pandemic
- MeSH terms
- COVID-19, SARS-CoV-2, Genetic Markers, United Kingdom, Humans, Mutation, Phylogeny, Genetic Variation, Genome, Viral, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
